Clinical Trial Update: Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating arginine butyrate with ganciclovir/valganciclovir in Epstein-Barr virus-associated lymphoid malignancies was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Lymphoid Malignancies
• Lymphoproliferative Disorders

Drugs mentioned

• Arginine butyrate (arginine butyrate)
• GANCICLOVIR (GANCICLOVIR SODIUM)
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: HemaQuest Pharmaceuticals Inc. | Conditions: EBV Lymphomas, Lympho-proliferative Diseases | Phase 2 | Status: TERMINATED